Abstract

G protein-coupled receptor (GPR)35 is highly expressed in the gastro-intestinal tract, predominantly in colon epithelial cells (CEC), and has been associated with inflammatory bowel diseases (IBD), suggesting a role in gastrointestinal inflammation. The enterotoxigenic Bacteroides fragilis (ETBF) toxin (BFT) is an important virulence factor causing gut inflammation in humans and animal models. We identified that BFT signals through GPR35. Blocking GPR35 function in CECs using the GPR35 antagonist ML145, in conjunction with shRNA knock-down and CRISPRcas-mediated knock-out, resulted in reduced CEC-response to BFT as measured by E-cadherin cleavage, beta-arrestin recruitment and IL-8 secretion. Importantly, GPR35 is required for the rapid onset of ETBF-induced colitis in mouse models. GPR35-deficient mice showed reduced death and disease severity compared to wild-type C57Bl6 mice. Our data support a role for GPR35 in the CEC and mucosal response to BFT and underscore the importance of this molecule for sensing ETBF in the colon.

Boleij et al. show that G protein-coupled receptor 35 (GPR35) regulates the responses to enterotoxigenic Bacteroides fragilis (ETBF) in colonic epithelial cells. They find that GPR35-deficiency nearly protected mice from ETBF-induced death, suggesting the importance of GPR35 in sensing ETBF in the colon.

Details

Title
G-protein coupled receptor 35 (GPR35) regulates the colonic epithelial cell response to enterotoxigenic Bacteroides fragilis
Author
Boleij Annemarie 1   VIAFID ORCID Logo  ; Fathi Payam 2 ; Dalton, William 3 ; Park, Ben 4 ; Wu Xinqun 2 ; Huso, David 5 ; Allen Jawara 2 ; Besharati Sepideh 6   VIAFID ORCID Logo  ; Anders, Robert A 6 ; Housseau Franck 7   VIAFID ORCID Logo  ; Mackenzie, Amanda E 8 ; Jenkins, Laura 8 ; Milligan, Graeme 8   VIAFID ORCID Logo  ; Wu, Shaoguang 2 ; Sears, Cynthia L 2   VIAFID ORCID Logo 

 Division of Infectious Diseases, Johns Hopkins University, Department of Medicine, Baltimore, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Radboud Institute for Molecular Life sciences (RIMLS), Radboud University Medical Center (Radboudumc), Department of Pathology, Nijmegen, The Netherlands (GRID:grid.461760.2) 
 Division of Infectious Diseases, Johns Hopkins University, Department of Medicine, Baltimore, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847) 
 Department of Oncology Center-Hematologic Malignancies, Johns Hopkins University, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Department of Oncology Center-Hematologic Malignancies, Johns Hopkins University, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916) 
 Department of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Department of Pathobiology, Johns Hopkins University, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 Department of Oncology Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, USA (GRID:grid.280502.d) (ISNI:0000 0000 8741 3625) 
 University of Glasgow, Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary and Life Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2527361833
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.